KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Receivables (2017 - 2025)

Historic Receivables for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $4.5 million.

  • Bionano Genomics' Receivables fell 1800.72% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 1800.72%. This contributed to the annual value of $4.9 million for FY2024, which is 5139.0% down from last year.
  • Bionano Genomics' Receivables amounted to $4.5 million in Q3 2025, which was down 1800.72% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Receivables ranged from a high of $10.1 million in Q4 2023 and a low of $3.5 million during Q1 2025
  • For the 5-year period, Bionano Genomics' Receivables averaged around $6.1 million, with its median value being $5.5 million (2024).
  • As far as peak fluctuations go, Bionano Genomics' Receivables surged by 9174.77% in 2021, and later crashed by 6039.35% in 2025.
  • Bionano Genomics' Receivables (Quarter) stood at $5.3 million in 2021, then soared by 40.88% to $7.5 million in 2022, then soared by 35.33% to $10.1 million in 2023, then tumbled by 51.39% to $4.9 million in 2024, then fell by 8.21% to $4.5 million in 2025.
  • Its Receivables was $4.5 million in Q3 2025, compared to $3.6 million in Q2 2025 and $3.5 million in Q1 2025.